A New Approach to Protecting Memory
Targeting neuronal dysfunction at its source
Casp-Aid is advancing CIM765, a clinically tested Caspase-1 inhibitor, toward Phase II, pursuing a differentiated strategy focused on neurons and their relationship to cognition.
OUR LEAD PROGRAM CIM765
Focused on cognition
CIM765 is an oral, brain-penetrant small molecule targeting Caspase-1, an upstream activator of Caspase-6, a pathway implicated in neuronal dysfunction and cognitive impairment.
Orally administered
Brain-penetrant
Advancing to Phase II
Grounded in human biology